Analysts Set vTv Therapeutics Inc. (NASDAQ:VTVT) Price Target at $55.83

vTv Therapeutics Inc. (NASDAQ:VTVT) has received an average rating of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $55.8333.

A number of equities research analysts have weighed in on the company. Wall Street Zen lowered vTv Therapeutics from a “buy” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings lowered vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. BTIG Research lifted their price objective on vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price objective for the company. Finally, HC Wainwright dropped their target price on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a report on Thursday, August 6th.

Hedge Funds Weigh In On vTv Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. purchased a new position in vTv Therapeutics during the fourth quarter valued at approximately $221,000. 683 Capital Management LLC purchased a new stake in vTv Therapeutics during the fourth quarter worth $731,000. Finally, Geode Capital Management LLC lifted its holdings in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares during the period. 17.51% of the stock is currently owned by institutional investors.

vTv Therapeutics Stock Performance

Shares of NASDAQ:VTVT opened at $33.89 on Tuesday. The firm’s 50 day simple moving average is $33.34 and its 200-day simple moving average is $34.60. vTv Therapeutics has a one year low of $15.79 and a one year high of $44.00. The firm has a market cap of $133.53 million, a PE ratio of -31.97 and a beta of 0.29.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). Equities research analysts predict that vTv Therapeutics will post -2.35 EPS for the current fiscal year.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.